Kane Biotech Inc.
KNE.V
TSX
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Net Income | 219.83% | 219.56% | 230.55% | 221.68% | -32.75% |
| Total Depreciation and Amortization | -11.40% | -9.90% | -9.00% | -5.53% | -9.81% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -503.34% | -543.75% | -686.89% | -858.65% | 383.62% |
| Change in Net Operating Assets | -305.40% | -244.58% | -219.09% | -265.16% | 1,128.48% |
| Cash from Operations | -95.51% | -95.61% | -163.12% | -132.12% | 33.25% |
| Capital Expenditure | -126.42% | -167.65% | -994.44% | -1,408.33% | -135.56% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -129.77% | -7.27% | 1,478.45% | 1,086.01% | 2,093.59% |
| Cash from Investing | 364.13% | 1,341.56% | 9,861.64% | 7,264.33% | 1,962.25% |
| Total Debt Issued | -- | -- | -100.00% | -1.18% | -67.06% |
| Total Debt Repaid | -918.06% | -1,279.81% | -1,775.17% | -2,734.04% | -103.79% |
| Issuance of Common Stock | 398.46% | 49.07% | -40.12% | -- | -57.35% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -1,082.98% | -822.18% | -701.81% | -2,273.26% | 145.06% |
| Cash from Financing | -763.44% | -451.70% | -448.25% | -997.61% | -73.28% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -267.38% | -292.05% | -389.91% | 91.21% | 497.52% |